絞り込み

16638

広告

Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.

著者 Wang Z , Zhao K , Zhang Y , Duan X , Zhao Y
Pharm Res.2019 Aug 08 ; 36(10):145.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (12view , 0users)

Full Text Sources

Miscellaneous

The immediate plasma metabolism and development of chemo-resistance (single agent) severely hampers the clinical effectiveness of Sorafenib (SRF) in liver cancer therapy. MicroRNA27a inhibition is a promising biological strategy for breast cancer therapy.
PMID: 31396764 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード